TIDMABDX

Abingdon Health PLC

07 March 2023

Abingdon Health plc

("Abingdon Health" or "the Company")

AppDx (R) lateral flow smartphone reader granted further patent

York, U.K. 7 March 2023: Abingdon Health plc (AIM: ABDX), a leading international lateral flow contract development and manufacturing organisation (CDMO), announces the granting of an additional patent for its AppDx (R) lateral flow smartphone reader.

AppDx (R) is a software development kit (SDK) for reading colorimetric lateral-flow tests (LFT) organized for Android(TM) and iOS(R) smartphone operating systems. AppDx (R) enables lateral-flow test readout from your pocket, enabled by a smartphone camera, that can be used by any user app. It consists of a software Application Programming Interface (API) accessed as a library which contains algorithms for image processing and deep learning in order to read a lateral-flow test using a smartphone. The algorithms need to be customized and tuned for each test. The Abingdon Health AppDx (R) algorithm reads the lateral flow device qualitatively (e.g. positive/negative) and semi-quantitively (e.g. negative/high/medium/low). A key point of differentiation is that the algorithm may be located on the smartphone, therefore not requiring a Wifi connection or 4G connection. It can also be provided as a web server-based solution.

The granted patent (GB 2601978) relates to the use of a plurality of captured images to provide a more refined algorithm which allows variations in imaging conditions to be averaged out and/or outliers removed. This allows the algorithm to counteract typically seen issues with measuring lateral flow devices such as specks of dust, reflections other artefacts and importantly different lighting conditions. These are important factors when considering the use of lateral flow tests in a range of different environments such as the home, doctor's office, veterinary office, farm or field. This innovation therefore is of critical importance in enabling the application of AppDx (R) commercially across a range of applications.

This is the third patent granted to Abingdon Health in relation to AppDx (R), including the granting of patent GB 2583419 which covers the use of neural-network based detection of lateral-flow tests, extracting the region-of-interest, and processing the data to calculate the values of the assay lines. This covers the two-stage pipeline where the assay area is extracted from the picture and image processing algorithms measure the line values and positions.

Chris Yates, CEO of Abingdon Health plc, commented: "We are pleased to announce the granting of a further patent for our AppDx (R) smartphone lateral flow reader. Given the expected rapid growth in the lateral flow self-test market we believe the use of smartphone apps, such as AppDx(R), will be critical in allowing widespread adoption of lateral flow rapid-testing.

"This patent grant underlines Abingdon's focus on innovation to support its customers and we now look forward to initiating commercial discussions to bring this product to market."

Enquiries

 
 Abingdon Health plc                                   www.abingdonhealth.com/investors/ 
 Chris Yates, Chief Executive Officer                                    Via Walbrook PR 
 Melanie Ross , Chief Financial Officer 
 
   Walbrook PR Limited               Tel: +44 (0)20 7933 8780 or abingdon@walbrookpr.com 
 Paul McManus / Phillip Marriage                  Mob: +44 (0)7980 541 893 / +44 (0)7867 
  Alice Woodings                                                                 984 082 
                                                                     +44 (0)7407 804 654 
 
 

About Abingdon Health plc

Abingdon Health is a leading lateral flow contract development and manufacturing organisation ("CDMO") offering its services to an international customer base across industry sectors that include clinical, animal health, plant health, and environmental testing. Abingdon Health has the internal capabilities to take projects from initial concept through to routine and large-scale manufacturing; from "idea to commercial success."

The Company's CDMO division offers product development, regulatory support, technology transfer and manufacturing services for customers looking to develop new assays or transfer existing laboratory-based assays to a lateral flow format. Abingdon Health aims to support the increase in need for rapid results across many industries and locations and produces lateral flow tests in areas such as infectious disease, clinical testing including companion diagnostics, animal health and environmental testing. Faster access to results allows for rapid decision making, targeted intervention and can support better outcomes.

Abingdon Health's Abingdon Simply Test range of self-tests is an ecommerce platform that offers a range of self-tests to empowers consumers to manage their own health and wellbeing. The Abingdon Simply Test ecommerce site offers consumers a range of information to support them in making informed decisions on the tests available. In addition, the site provides Abingdon's contract services customers with a potential route to market for self-tests. The Abingdon Simply Test range is also sold through international distributors and through other channels in the UK and Ireland such as pharmacy chains.

Founded in 2008, Abingdon Health is headquartered in York, England.

For more information visit: www.abingdonhealth.com

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word "Reach" in the source column of the News Explorer pages of London Stock Exchange's website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NRAUPUAGWUPWGBQ

(END) Dow Jones Newswires

March 07, 2023 02:00 ET (07:00 GMT)

Abingdon Health (LSE:ABDX)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Abingdon Health Charts.
Abingdon Health (LSE:ABDX)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Abingdon Health Charts.